Get the Stockscreener App
1.13
7.28%
0.10
Jaguar Health Inc stock is traded at $1.13, with a volume of 182.12K.
It is up +7.28% in the last 24 hours and up +2.31% over the past month.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
See More
Previous Close:
$1.03
Open:
$1.03
24h Volume:
182.12K
Relative Volume:
0.89
Market Cap:
$4.72M
Revenue:
$10.48M
Net Income/Loss:
$-37.74M
P/E Ratio:
-0.0698
EPS:
-16.1846
Net Cash Flow:
$-29.03M
1W Performance:
+11.48%
1M Performance:
+2.31%
6M Performance:
-57.17%
1Y Performance:
-96.55%
1-Day Range:
$1.03
$1.14
1-Week Range:
$0.9174
$1.1099
52-Week Range:
$0.9174
$32.00
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415-371-8300
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
1.13 | 4.30M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.21 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.83 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.25 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
802.32 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.76 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
Jaguar Health reports PS reduction in pediatric intestinal failure study By Investing.com - Investing.com India
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication - ACCESS Newswire
Experimental drug lets some children rely less on IV nutrition support - Stock Titan
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Ventura County Star
Jaguar Health (JAGX) Secures $240,000 FDA Grant for Canine Diarr - GuruFocus
Jaguar Health (JAGX) Secures $240,000 FDA Grant for Canine Diarrhea Study - GuruFocus
Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - San Luis Obispo Tribune
FDA backs study of new treatment for chemo-related diarrhea in dogs - Stock Titan
Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts - Norwich Bulletin
Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID) - Montgomery Advertiser
Aug Big Picture: Why hedge funds are buying Jaguar Health Inc stock2025 Top Gainers & Community Supported Trade Ideas - moha.gov.vn
Jaguar Health (JAGX) Reports Promising Trials for Crofelemer in UAE - GuruFocus
Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026 - Burlington Free Press
Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates - Hillsdale Daily News
What analysts say about Jaguar Health Inc stockPrice Action Analysis & Free Stock Index Interpretations - earlytimes.in
Why Jaguar Health Inc. stock remains on watchlists2025 Short Interest & Entry and Exit Point Strategies - Улправда
Sell Signal: Why Jaguar Health Inc 1JA0 stock benefits from AI revolution2025 Geopolitical Influence & Weekly Watchlist for Hot Stocks - moha.gov.vn
Aug PreEarnings: How Jaguar Health Inc. stock reacts to oil prices2025 Investor Takeaways & Target Return Focused Stock Picks - Улправда
Can Jaguar Health Inc. stock deliver surprise earnings beatJuly 2025 News Drivers & Momentum Based Trading Ideas - Улправда
Jaguar Health Earnings Notes - Trefis
How Jaguar Health Inc. stock reacts to oil prices2025 Market WrapUp & Stock Market Timing Techniques - Улправда
Why Jaguar Health Inc. stock could see breakout soonTrade Risk Report & Long-Term Safe Investment Ideas - DonanımHaber
Why analysts recommend Jaguar Health Inc. (1JA0) stockJuly 2025 Retail & Real-Time Volume Analysis Alerts - DonanımHaber
Will Jaguar Health Inc. stock split attract more investorsQuarterly Market Summary & High Return Trade Opportunity Guides - DonanımHaber
Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts - Pensacola News Journal
Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF) - Hornell Evening Tribune
Jaguar Health director gets 5,870 RSUs and 5,870 options | JAGX SEC FilingForm 4 - Stock Titan
Jaguar Health submits abstract on crofelemer for short bowel syndrome By Investing.com - Investing.com Canada
Jaguar Health submits abstract on crofelemer for short bowel syndrome - Investing.com India
Jaguar Health (JAGX) Advances Treatment for Short Bowel Syndrome - GuruFocus
Jaguar Health (NASDAQ: JAGX) advances crofelemer program in SBS-IF, MVID trials - Stock Titan
Jaguar Health executes strategic stock exchange agreements - MSN
Jaguar Health Executes Strategic Stock Exchange Agreements - TipRanks
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs - The Florida Times-Union
Jaguar Health Inc (JAGX) is looking forward to a strong quarter - setenews.com
Jaguar Health Inc Stock (JAGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):